Which condition is not an FDA label indication for Hydrochlorothiazide and Triamterene?

Hydrochlorothiazide and Triamterene are commonly used together as a combination medication primarily for their effects on managing fluid retention and blood pressure. While all the other conditions listed—Edema, Hypertension, and Heart Failure—are FDA-approved indications for this medication, Diabetes Insipidus is not.

Hydrochlorothiazide is a thiazide diuretic that helps eliminate excess fluid by increasing urine output, making it effective for treating Edema and Hypertension. It is often used in conjunction with Triamterene, a potassium-sparing diuretic, to counteract the potassium loss that can result from thiazide diuretics. Consequently, this combination is also beneficial for patients with Heart Failure, as it helps reduce fluid overload while maintaining potassium levels.

In contrast, Diabetes Insipidus is a condition characterized by the inability of the body to concentrate urine, leading to excessive urination and thirst. This condition is typically treated with different medications that help control the levels of vasopressin or manage the symptoms associated with fluid loss. Therefore, the combination of Hydrochlorothiazide and Triamterene does not hold an FDA label indication for treating Diabetes Insipidus, which is why it is the